Get started
Cyclo Therapeutics, Inc.Cyclo Therapeutics, Inc.Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CYTH chart


Full chart

CYTH upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪20.56 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.8823 USD
Net income (FY)
‪−20.06 M‬ USD
Revenue (FY)
‪1.08 M‬ USD
Shares float
‪16.61 M‬
Beta (1Y)
1.17

Employees


Employees (FY)
8
Change (1Y)
−1 −11.11%
Revenue / Employee (1Y)
‪134.55 K‬ USD
Net income / Employee (1Y)
‪−2.51 M‬ USD

About Cyclo Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Nathan Scott Fine
Website
cyclotherapeutics.com
Headquarters
Gainesville
Founded
1990
FIGI
BBG000LYRDD9
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CYTH news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CYTH is 0.7390 USD — it has increased by 3.15% in the past 24 hours. Watch Cyclo Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cyclo Therapeutics, Inc. stocks are traded under the ticker CYTH.
CYTH stock has risen by 2.64% compared to the previous week, the month change is a −2.69% fall, over the last year Cyclo Therapeutics, Inc. has showed a −57.53% decrease.
We've gathered analysts' opinions on Cyclo Therapeutics, Inc. future price: according to them, CYTH price has a max estimate of 4.00 USD and a min estimate of 0.95 USD. Watch CYTH chart and read a more detailed Cyclo Therapeutics, Inc. stock forecast: see what analysts think of Cyclo Therapeutics, Inc. and suggest that you do with its stocks.
CYTH reached its all-time high on Oct 4, 1995 with the price of 400.0000 USD, and its all-time low was 0.5946 USD and was reached on Sep 12, 2024. View more price dynamics on CYTH chart.
See other stocks reaching their highest and lowest prices.
CYTH stock is 3.99% volatile and has beta coefficient of 1.17. Track Cyclo Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cyclo Therapeutics, Inc. there?
Today Cyclo Therapeutics, Inc. has the market capitalization of ‪20.56 M‬, it has decreased by −7.21% over the last week.
Yes, you can track Cyclo Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Cyclo Therapeutics, Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
CYTH earnings for the last quarter are −0.21 USD per share, whereas the estimation was −0.15 USD resulting in a −35.48% surprise. The estimated earnings for the next quarter are −0.16 USD per share. See more details about Cyclo Therapeutics, Inc. earnings.
Cyclo Therapeutics, Inc. revenue for the last quarter amounts to ‪123.10 K‬ USD, despite the estimated figure of ‪267.50 K‬ USD. In the next quarter, revenue is expected to reach ‪294.00 K‬ USD.
CYTH net income for the last quarter is ‪−5.98 M‬ USD, while the quarter before that showed ‪−4.34 M‬ USD of net income which accounts for −37.72% change. Track more Cyclo Therapeutics, Inc. financial stats to get the full picture.
No, CYTH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 8.00 employees. See our rating of the largest employees — is Cyclo Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cyclo Therapeutics, Inc. EBITDA is ‪−21.14 M‬ USD, and current EBITDA margin is ‪−1.86 K‬%. See more stats in Cyclo Therapeutics, Inc. financial statements.
Like other stocks, CYTH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cyclo Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cyclo Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cyclo Therapeutics, Inc. stock shows the sell signal. See more of Cyclo Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.